Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE I: Efficacy of Quadrivalent HPV Vaccine (V501)
NCT00092521Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2001
- Primary completion
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC), genital warts, cervical intraepithelial neoplasia (CIN) and 5 more (3 arms), sponsored by Merck & Co. Primary endpoints: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer at 4 years and Incidence of HPV 6/11/16/18-related External Genital Lesions (EGL) at 4 years. Started Dec 2001; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)genital wartscervical intraepithelial neoplasia (CIN)adenocarcinoma in situ (AIS)vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NCT00092521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092521.